71879-55-5

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-PIPERIDIN-4-YLPROPANOATE is used as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients. Its role in drug development is crucial, as it contributes to the creation of new medications with potential therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical sector, ETHYL 3-PIPERIDIN-4-YLPROPANOATE is employed in the production of various products. Its application in this industry is essential for the development of effective and safe agrochemicals that contribute to agricultural productivity and crop protection.
Used in Flavor and Fragrance Industry:
ETHYL 3-PIPERIDIN-4-YLPROPANOATE is used as a flavoring agent and a plant metabolite in the flavor and fragrance industry. Its mild, fruity odor makes it an ideal component for adding pleasant scents to products such as perfumes, soaps, and lotions, enhancing their appeal to consumers.

Upstream product

• 872-85-5 pyridine-4-carbaldehyde 
• 1822-32-8 3-(4-piperidyl)propionic acid 
• 24489-96-1 ethyl 3-(pyridin-4-yl)prop-2-enoate 
• 162504-86-1 t-butyl 4-(3-ethoxy-3-oxoprop-1-enyl)-tetrahydropyridine-1(2H)-carboxylate 
• 301232-45-1 tert-butyl 4-(3-ethoxy-3-oxopropyl)-1-piperidinecarboxylate 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 664364-13-0 benzyl 4-((1E)-3-ethoxy-3-oxoprop-1-en-1-yl)piperidine-1-carboxylate 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 123293-78-7 ethyl 3-(4-pyridinyl)-(2E)-propenoate 

Downstream Products

• 51144-70-8 ethyl 3-(1-benzoylpiperidin-4-yl)propanoate 
• 99197-86-1 ethyl 1-[(phenylmethoxy)carbonyl]-4-piperidinepropanoate 
• 301232-45-1 tert-butyl 4-(3-ethoxy-3-oxopropyl)-1-piperidinecarboxylate 
• 374776-39-3 4-(2-ethoxy-5-(4-(2-ethoxycarbonylethyl)piperidinylsulfonyl)benzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 374776-40-6 4-(5-(4-(2-ethoxycarbonylethyl)piperidinylsulfonyl)-2-n-propoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 70724-83-3 N-methyl-3-(piperid-4-yl)propionamide 
• 1305197-29-8 N-hydroxy-3-(1-phenylmethanesulfonyl-piperidin-4-yl)-propionamide 
• 1305197-30-1 3-(1-benzenesulfonyl-piperidin-4-yl)-N-hydroxy-propionamide 
• 1305197-32-3 N-hydroxy-3-(1-phenylacetyl-piperidin-4-yl)-propionamide 
• 339333-00-5 ethyl 3-(1-benzylpiperidin-4-yl)propionic acid 
• 1454273-51-8 ethyl 5-(1-benzylpiperidin-4-yl)-3-oxopentanoate 
• 1454273-52-9 ethyl 5-(1-benzylpiperidin-4-yl)-2-diazo-3-oxopentanoate 
• 1454273-53-0 ethyl 8-benzyl-2-oxo-8-azaspiro[4.5]decane-1-carboxylate 
• 1454273-54-1 ethyl 8-benzyl-2-ureido-8-azaspiro[4.5]dec-1-ene-1-carboxylate 

Relevant academic research and scientific papers

PRODUCTION METHOD OF CYCLIC COMPOUND

PROBLEM TO BE SOLVED: To provide an industrially simple production method of a cyclic compound. SOLUTION: A production method of a cyclic compound includes a step to obtain a reduced form (B) by reducing an unsaturated bond in a ring structure of an aromatic compound (A) by means of catalytic hydrogenation of the aromatic compound (A) or its salt using palladium carbon as a catalyst under a normal pressure, in which the aromatic compound (A) has one or more ring structures selected from a group consisting of a five membered-ring, a six membered-ring, and a condensed ring of the five membered-ring or the six membered-ring with another six membered-ring, a hetero atom can be included in the ring structure, and the aromatic compound (A) can have one or two side chains bonded to the ring structure and does not have any carbon-carbon triple bond in the side chain. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors. A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition. Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells.

FUSED BENZENE DERIVATIVE AND USE

The present invention provides a compound represented by the general formula: [wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents a further optionally substituted 4- to 10-membered ring, Ring C represents a further optionally substituted benzene ring, X1 represents carbon atom, X2 represents a carbon atom, an oxygen atom, etc., W represents a nitrogen atom, etc., Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group, etc., and R3' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group, etc., and R5' represents a hydrogen atom, a cyano group, a nitro group, etc., respectively), etc., and R1 represents an electron-withdrawing group, respectively. The formula represents a single bond or a double bond] or a salt thereof, which is useful as an androgen receptor modulator.

Tricycle substituted with azaheterocyclic carboxylic acids

The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula wherein X, Y, Z, R1, R2 and r are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonizing peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Central cholinergic agents. IV. Synthesis and acetylcholinesterase inhibitory activities of ω-[N-ethyl-N-(phenylmethyl)amino]-1-phenyl-1-alkanones and their analogues with partial conformational restriction

Inhibitors of acetylcholinesterase (AChE) bave been designed based on a working hypothesis of the enzyme's active site. These compounds were tested for their inhibitory activities on AChE and ω-[N-ethyl-N-(phenylmethyl)amino]-1-phenyl-1-alkanones (3) were found to be potent inhibitors. Various analogues of 3 were prepared to study the effect on AChE inhibition of partial restriction of conformation. Compounds with potent AChE inhibition were further evaluated in terms of central selectivity: the ratio of central action (ameliorating effect on scopolamine-induced memory impairment using a T-maze alternation task) to peripheral action.